1. Home
  2. CUE vs VANI Comparison

CUE vs VANI Comparison

Compare CUE & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$27.00

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Logo Vivani Medical Inc. (DE)

VANI

Vivani Medical Inc. (DE)

HOLD

Current Price

$1.44

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUE
VANI
Founded
2014
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
124.5M
119.0M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
CUE
VANI
Price
$27.00
$1.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$120.00
$3.50
AVG Volume (30 Days)
160.0K
300.2K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
61.11
N/A
EPS
N/A
N/A
Revenue
$27,466,000.00
$4,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
195.75
N/A
52 Week Low
$0.17
$0.92
52 Week High
$45.50
$1.92

Technical Indicators

Market Signals
Indicator
CUE
VANI
Relative Strength Index (RSI) 44.09 52.82
Support Level $24.49 $1.24
Resistance Level $33.73 $1.55
Average True Range (ATR) 3.15 0.07
MACD -0.78 -0.00
Stochastic Oscillator 16.97 51.00

Price Performance

Historical Comparison
CUE
VANI

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About VANI Vivani Medical Inc. (DE)

Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.

Share on Social Networks: